Dynamic Changes of HER2 Expression in Breast Cancers after Neoadjuvant Chemotherapy with the Inclusion of HER2-low Category

被引：0
|
作者：
Karakas, Cansu [1 ]
Tyburski, Haley [2 ]
Liu, Elena [1 ]
Hicks, David [1 ]
Zhang, Huina [1 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Univ Rochester, Rochester, NY USA
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
163
引用
收藏
页码：S151 / S152
页数：2
相关论文
共 50 条
  • [31] HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
    Mengyuan Cai
    Ming Li
    Hong Lv
    Shuling Zhou
    Xiaoli Xu
    Ruohong Shui
    Wentao Yang
    BMC Cancer, 23
  • [32] HER2-Low Breast Cancer: Evolution of HER2 expression from Primary Tumor to Distant Metastases
    Cai, Mengyuan
    Li, Ming
    Lv, Hong
    Zhou, Shuling
    Xu, Xiaoli
    Shui, Ruohong
    Yang, Wentao
    LABORATORY INVESTIGATION, 2023, 103 (03) : S107 - S109
  • [33] HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
    Cai, Mengyuan
    Li, Ming
    Lv, Hong
    Zhou, Shuling
    Xu, Xiaoli
    Shui, Ruohong
    Yang, Wentao
    BMC CANCER, 2023, 23 (01)
  • [34] Neoadjuvant chemotherapy for breast cancer - analysis of changes in breast cancer phenotype, hormonal and HER2 expression
    Badr, N.
    Danial, I.
    Rea, D.
    Steven, J.
    Shaaban, A.
    VIRCHOWS ARCHIV, 2020, 477 : S42 - S43
  • [35] Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
    Xia, Lin-Yu
    Cao, Xu-Chen
    Yu, Yue
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [36] The Dynamic of HER2-low Expression during Breast Cancer Progression
    Anderson, Sarah
    Bartow, Brooke
    Huang, Xiao
    Wei, Shi
    LABORATORY INVESTIGATION, 2023, 103 (03) : S89 - S89
  • [37] Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer
    Qiao, Weiqiang
    Guo, Wanying
    Liu, Qipeng
    Guo, Xiao
    Deng, Miao
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 64
  • [38] Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
    Anthony Bergeron
    Aurélie Bertaut
    Françoise Beltjens
    Céline Charon-Barra
    Alix Amet
    Clémentine Jankowski
    Isabelle Desmoulins
    Sylvain Ladoire
    Laurent Arnould
    British Journal of Cancer, 2023, 129 : 122 - 134
  • [39] Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns
    Lv, Hong
    Bai, Qian-Ming
    Li, Ming
    Cai, Meng-Yuan
    Zhou, Shu-Ling
    Liu, Yin
    Wang, Zhong-Hua
    Shui, Ruo-Hong
    Lu, Hong-Fen
    Xu, Xiao-Li
    Yu, Bao-Hua
    Tu, Xiao-Yu
    Bi, Rui
    Cheng, Yu-Fan
    Zhou, Xiao-Yan
    Shao, Zhi-Min
    Yang, Wen-Tao
    JOURNAL OF CLINICAL PATHOLOGY, 2024,
  • [40] Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer
    Yang, Yu-Feng
    Liao, Ying-Yang
    Li, Le-Qun
    Xie, Shu-Rui
    Xie, Yan-Fang
    Peng, Ning-Fu
    PATHOLOGY RESEARCH AND PRACTICE, 2013, 209 (12) : 797 - 802
12345